Breast cancer: Demographic characteristics and clinico-pathological presentation of patients in Iraq;Cancer du sein: Caractéristiques démographiques des patientes et présentation clinico-pathologique en Iraq

Eastern Mediterranean Health Journal

Volumn 16, Issue 11, 2010, Pages 1159-1164

  Alwan, N A S ^a  

^a UNIVERSITY OF BAGHDAD   (Iraq)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGE; AGED; ANEUPLOIDY; ARTICLE; ASPIRATION BIOPSY; BREAST CANCER; BREAST SELF EXAMINATION; BREAST TUMOR; CANCER GRADING; CANCER STAGING; CLINICAL FEATURE; CONSULTATION; DEMOGRAPHY; DNA DETERMINATION; ECHOMAMMOGRAPHY; FAMILY HISTORY; FEMALE; HEALTH PROGRAM; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; INTRADUCTAL CARCINOMA; IRAQ; LACTATION; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MARRIAGE; MASTECTOMY; PALPATION; URBAN AREA;

EID: 78650251755     PISSN: 10203397     EISSN: None     Source Type: Journal    
DOI: 10.26719/2010.16.11.1159     Document Type: Article

References (32)

1. Parkin DM et al. Global cancer statistics 2002, CA: A Cancer Journal for Clinicians, 2005, 55:74-108.
2. Parkin DM, Fernandez LM. Use of statistics to assess the global burden of breast cancer. Breast, 2006, 12(1 Suppl.):S70-S80.
3. Anderson BO et al. Guideline implementation for breast healthcare in low-income and middle-income countries. Overview of the Breast Health Global Initiative Global Summit, 2007. Cancer, 2008, 113(8 Suppl.):2221-2243.
4. Iraqi Cancer Board. Results of the Iraqi Cancer Registry 2004. Baghdad, Iraqi Cancer Registry Center, Ministry of Health, 2007.
5. National Cancer Control Programs. Policies and managerial guidelines, 2nd. ed. Geneva, World Health Organization, 2002.
6. Edge SB et al. AJCC Cancer Staging Manual, 7th ed. New York, Springer-Verlag, 2010.
7. American Joint Committee on Cancer. The breast. In: AJCC cancer staging manual, 6th ed. New York, Springer, 2002:171-180.
8. Rosai J, ed. Rosai and Ackerman's surgical pathology: breast, 9th ed, vol. II. St. Louis, Mosby, 2004:1763-1839.
9. Auer GU. DNA and prognosis in breast cancer [thesis]. Stockholm, Karolinska Institute, 1986.
10. Marrazo A et al. Immunocytochemical determination of oestrogen and progesterone receptors on 219 FNA of breast cancer. Anticancer Research, 1995; 15: 521-526.
11. Revised global burden of disease (GBD), WHO 2002 estimates. Geneva, World Health Organization, 2003 (http:// www.who.int/healthinfo/bodgbd2002revised/en/index. html, accessed 1 September 2009).
12. Rastogi T, Hildesheim A, Sinha R. Opportunities for cancer epidemiology in developing countries. Nature Reviews Cancer, 2004, 4(11):909-17.
13. Fakhro A et al. Breast cancer: patient characteristics and survival analysis at Salmaniya Medical Complex, Bahrain. Eastern Mediterranean Health Journal, 1999, 5(3):430-439.
14. Omar S et al. Breast cancer in Egypt: A review of disease presentation and detection strategies. Eastern Mediterranean Health Journal, 2003, 9(3):448-461.
15. Rennert G. Breast cancer. In: Freedman L et al. Cancer incidence in four member counties (Cyprus, Egypt, Israel and Jordan) of the Middle East Cancer Consortium (MECC) compared to SEER. Bethesda, Maryland, NCI (NIH Pub. No. 06-5873), 2006:73-81.
16. Miller AB. Mammography; a critical evaluation of its role in breast cancer screening, especially in developing countries. Journal of Public Health Policy, 1989, 10:486-497.
17. Tada T, Kasumi F. Characteristics of familial breast cancer. Nippon-Rinsho, 2000, 7(58):1405-1408.
18. Anynawu S. Breast cancer in eastern Nigeria: a ten year review. West African Journal of Medicine, 2000, 19(2):120-125.
19. Alwan A et al. Community control of genetic and congenital disorders. Cairo, World Health Organization, 1997 (Technical Publications Series 24:63-79
20. ISA Hospital Cancer Registry, Tunisia. Registre de l'institut Salah Azaiz 1994-1999. Tunis, Ministère de la Santé, Institut Salah Azaiz, 2000.
21. IARC Working Group on the Evaluation of Cancer-Preventive Strategies. Breast cancer screening. Lyon, World Health Organization, 2002.
22. Etzioni R et al. The case for early detection. Nature Reviews Cancer, 2003, 3(4):243.
23. Harris GC, Pinder SE, Elson CW. The role of the pathologist in assessing prognostic factors for breast cancer. In: Walker RA. Prognostic and predictive factors in breast cancer. London, Martin Dunitz Group, 2003:7-22.
24. Fallenius AG, Auer GU, Carstensen JM. Prognostic signifcance of DNA measurements on 409 consecutive breast cancer patients. Cancer,1988, 62:331-341.
25. Kronenwett U, Ploner A, Zetterberg A et al. Genomic instability and prognosis in breast carcinomas. Cancer Epidemiology Biomarkers & Prevention, AACR, 2006, 15:6030-6035.
26. Al-Alwan N. DNA proliferative index as a marker in Iraqi aneuploid mammary carcinoma. Eastern Mediterranean Health Journal, 2000, 6(5/6):1062-1072.
27. Al-Alwan N, Al Kubaisi W, Al Rawaq K. Assessment of response to Tamoxifen in Iraqi patients with advanced Breast Cancer. Eastern Mediterranean Health Journal, 2000, 6(3/4):475-482.
28. Elledge RM and Allred DC. Clinical aspects of estrogen and progesterone receptors. In: Harris JR et al., editors. Diseases of the breast. Philadelphia, Lippincott Williams & Wilkins, 2004:603-17.
29. Khorshid OM et al. Prognostic signifcance of HER2/neu onco-gene in breast cancer patients. Cairo, National Cancer Institute, Scientifc Annual Report, 2002.
30. Boulos S et al. Breast screening in the emerging world: high prevalence of breast cancer in Cairo. The Breast, 2005, 14:340-346.
31. Devi B, Tang TS, Corbex M. Reducing by half the percentage of late-stage presentation for breast and cervix cancer over 4 years: a pilot study of clinical downstaging in Sarawak, Malaysia. Annals of Oncology, 2007, 18(7):1172-1176.
32. Mellstedt H. Cancer initiatives in developing countries. Annals of Oncology, 2006, 17(Suppl. 8):viii24-viii31.